Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see whether the combination of avelumab and talazoparib can
be an effective treatment for metastatic renal cell carcinoma.